2016年10月28日，华润医药集团有限公司（简称“华润医药”， 股票代码：3320) 在金杜律师事务所协助下正式在香港联交所主板上市。华润医药本次全球共发行15.43亿股，每股发行价为9.10港元，总募资金净额约为136.71亿港元，成为2016年港股市场最大非金融类IPO。如后续全额执行超额配售选择权，将成为有史以来最大中资医药IPO、全球排名第六位的医药类IPO。
On 28 October 2016, China Resources Pharmaceutical Group Ltd. (“CR Pharmaceutical”, stock code: 3320) had its H shares listed on the main board of the Hong Kong Stock Exchange, with King & Wood Mallesons (KWM) advising its underwriters. CR Pharmaceutical issued a total of 1.543 billion shares globally on an offer price of HK$9.10 per share, and raised a net amount of approximately HK$13.671 billion, making it the largest IPO conducted by non-financial enterprises in Hong Kong’s capital market in 2016. If over-allotment option is fully exercised, this transaction will be the largest-ever IPO by pharmaceutical enterprises in China and the sixth in pharmaceutical industry globally.
Read The Full Article Please Click Here